Anti-tumor necrosis factor (TNF) agents are recommended as a treatment for both symptomatic and asymptomatic DAD2 as they prevent or eliminate manifestations of autoinflammatory disease and vasculitis, reduce the risk of ischemic stroke, reduce the inflammatory burden, and ameliorate immunodeficiency, hepatosplenomegaly, and neutropenia [140]. Here, TNF is linked to Hepatosplenomegaly.